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Abstract 
Objective: To examine the utility of the new Movement Disorder Society (MDS) 
diagnostic criteria in a large cohort of Parkinson’s disease (PD) patients. 
Methods: Recently diagnosed (<3.5 years) PD cases fulfilling step 1 of the United 
Kingdom (UK) brain bank criteria in Tracking Parkinson’s, a UK multicenter 
prospective natural history study, were assessed. 
Results: In 2000 cases, 1835 (91.7%) met MDS criteria for PD, either clinically 
established (n=1261, 63.1%) or clinically probable (n=574, 28.7%), leaving 165 
(8.3%) not fulfilling criteria. Clinically established cases were significantly more likely 
to have limb rest tremor (89.3%), a good L-dopa response (79.5%), and olfactory 
loss (71.1%), than clinically probable cases (60.6%, 44.4%, and 34.5% respectively), 
but differences between probable PD and ‘not PD’ cases were less evident. In cases 
not fulfilling criteria, the mean MDS UPDRS score (25.1, SD 13.2) was significantly 
higher than in probable PD (22.3, SD 12.7, p=0.016) but not established PD (22.9, 
SD 12.0, p=0.066). The L-dopa equivalent daily dose of 341mg (SD 261) in non-PD 
cases was significantly higher than in probable PD (250mg, SD 214, p<0.001) and  
established PD (308mg, SD 199, p=0.025). After 30 months’ follow-up, 89.5% of 
clinically established cases at baseline remained as PD (established/probable), and 
86.9% of those categorized as clinically probable at baseline remained as PD 
(established/probable). 
Conclusion: Over 90% of cases clinically diagnosed as early PD fulfilled the MDS 
criteria for PD. Cases not fulfilling PD criteria had more severe parkinsonism, in 
particular relating to postural instability, gait problems, and cognitive impairment.  
 
Introduction 
 
The accurate diagnosis of Parkinson’s disease (PD) assists patient management 
and healthcare planning, and the identification of effective new treatments, which is 
important for a disease with an increasing prevalence [1]. Clinical diagnostic 
accuracy is suboptimal, being around 80% based on an overview of 11 studies  
[2][3]. As there is no biomarker or specific imaging test for PD, the diagnosis relies 
heavily on clinical assessment [4]. Increased knowledge about PD and disorders that 
mimic it has allowed the development of new clinical Movement Disorder Society 
(MDS) diagnostic criteria [4]. These retain the core definition of parkinsonism 
(bradykinesia, rigidity and/or rest tremor) but do not allow for postural instability, 
compared to the United Kingdom (UK) Brain Bank criteria[5]. After confirmation of 
parkinsonism, a clinical diagnosis of PD according to the MDS criteria is based on: 
absolute exclusion criteria (which rule out PD), red flags (which must be 
counterbalanced by supportive criteria), and positive supportive criteria. These are 
combined to determine diagnostic certainty as clinically probable PD, or clinically 
established PD [4]. The new consensus criteria represent a summation of available 
knowledge, but have not been tested prospectively, which was the purpose of the 
current study. We classified and described the phenotype of cases recruited to an 
observational study of PD, according to fulfilment of the new MDS criteria [4].  
Methods 
Patients were recruited to Tracking Parkinson’s, a large prospective, UK multicenter 
project, as detailed elsewhere [6]. In brief, recent onset PD cases with a clinical 
diagnosis and fulfilling UK Brain Bank criteria at study entry [5] were recruited, 
including drug-naïve and treated patients. Those with severe comorbid illness, other 
degenerative parkinsonism, symmetrical lower body parkinsonism, drug-induced 
parkinsonism, or a clinical diagnosis of dementia at first assessment were excluded. 
Levodopa (L-dopa) equivalent daily doses (LEDD) were calculated using an 
established formula [7]. Motor subtypes were determined by established methods 
[8]. Montreal cognitive assessment (MoCA) scores were adjusted for years of 
education and categorized as (>23), mild cognitive impairment (MCI) (22-23, or less 
than 22 but without functional impairment), or dementia (21 or less with functional 
impairment) [9]. Olfaction testing used either the 40-item University of Pennsylvania 
Smell Identification Test (UPSIT) or Sniffin’ Sticks 16-item version (SS), and 
hyposmia defined as previously reported [10]. FP-CIT scanning was performed as 
part of routine care, on the basis of diagnostic uncertainty. 
As the MDS diagnostic criteria were published after patient recruitment was 
complete, each component was mapped to the assessments performed, including 
MDS UPDRS, lying and standing blood pressure, response to L-dopa test dose, non-
motor symptom scales, scales for outcome in autonomic symptoms in PD, PD and 
Epworth sleep score, and questionnaires for wearing off, rapid eye movement 
behavior disorder, constipation, Leeds anxiety and depression, and PD quality of life 
8. Clinicians assessed each case, at baseline (study entry) and after 1 and 2.5 
years, for any unusual or atypical features for PD, under several categories: clinical 
presentation, symptoms, signs, disease course, or therapy response. To ensure that 
early signs were not overlooked, such features were noted when they ‘could indicate 
an alternative diagnosis to PD (i.e. idiopathic parkinsonism with the presence of 
Lewy bodies in the substantia nigra), no matter how remote’. Clinicians also rated 
their clinical diagnostic certainty between 0% (not PD) and 100% (definite PD).  
There was some variance in the data elements collected, compared to the MDS 
criteria: we recorded vertical gaze palsy (rather than only downward vertical gaze 
palsy), and did not specifically note recurrent falls, inspiratory stridor, or frequent 
inspiratory sighs. We assessed for the absence of an observable L-dopa response 
following MDS criteria (daily L-dopa dose 600mg or more, and bradykinesia or 
rigidity in at least one body part exceeding 2 points), and carried out an additional 
exploratory analysis (no L-dopa dose threshold, MDS UPDRS 3 score above 20 to 
define at least moderate disease, and clinician assessment of ‘little or no response to 
L-dopa or a dopamine agonist’). For assessment of a clear and dramatic response to 
dopaminergic therapy, we used an improvement of over 30% in MDS UPDRS 3 after 
the patient’s usual morning L-dopa dose, taken after a practically defined overnight 
period off medication.  
 
Statistical analysis 
Regression models were used to test the association between the three MDS 
classification groups and clinical features. Regression was linear for continuous 
outcomes, logistic for binary outcomes, ordinal (also called proportional odds) for 
ordinal outcomes (MoCA and Hoehn and Yahr stage), and multinomial for motor 
subtype (using tremor dominant as the baseline category). Two-way p-values across 
the three MDS classification groups were calculated as 2-tailed, after adjustment for 
three confounders: age, gender and disease duration.  The linearity of age and 
disease duration was tested using fractional polynomials in univariate models, and 
then transformed if non-linear. The agreement between baseline and follow-up 
categorization was tested using weighted kappa, and also, because of imbalance of 
group sizes and numbers of cases changing category, by the weighted Gwet 
AC1/AC2 coefficient [11, 12]. Statistical analysis was conducted using STATA 
(version 14, StataCorp, Texas, USA). 
 
 
Results 
There were 2000 cases at study entry, mean age 64.4 years (SD 9.8), disease 
duration 1.3 years (SD 0.9), and 64.9% were male. 1835 (91.7%) met the MDS 
diagnostic criteria for PD, either clinically established (n=1261, 63.1% of all cases) or 
clinically probable (n=574, 28.7% of all cases), leaving 165 (8.3% of all cases) who 
did not meet criteria (Table 1). Tremor as a symptom at onset was significantly more 
prevalent in clinically established PD (83.3%) than clinically probable PD (57.4%), or 
those not fulfilling criteria for PD (62.6%), both p<0.001, and the proportion with a 
tremor dominant motor subtype followed the same pattern (Table 1). Cognition was 
worse in non-PD cases (21.7% dementia) compared to 15.5% dementia in clinically 
probable PD cases (p=0.013) and 13.0% dementia in clinically established PD cases 
(p=0.02). The MDS UPDRS 3 score was very similar for clinically established (22.9, 
SD 12.0) and clinically probable PD cases (22.3, SD 12.7), but was significantly 
higher in cases not fulfilling PD (25.1 SD 13.2, p=0.016 compared to clinically 
probable PD). The LEDD in the cases failing to meet MDS criteria for PD was 341mg 
(SD 261), which was significantly higher than those with clinically probable PD 
(250mg, SD 214, p<0.001), and in those with clinically established PD (308mg, SD 
199, p=0.025).  
The numbers of red flags, supporting criteria, and absolute exclusions categorized 
by MDS diagnostic group are in Table 2. Most non-PD cases were categorized on 
the basis of one or more absolute exclusion (149 of 165 cases, 90.3%), rather than 
having an excess of red flags over supporting features (15 of 165, 9.1%), or having 
>2 red flags (1 of 165, 0.6%). In these non-PD cases, the most common exclusion 
criteria were vertical gaze palsy (n=117, 70.9% of cases not meeting PD criteria, or 
5.8% of all cases) and cerebellar features (n=25, 15.2% of cases not meeting PD 
criteria, or 1.3% of all cases). Only 3 cases (0.2%) were excluded (and thereby 
categorized as non-PD) on the basis of an absent L-dopa response defined by the 
MDS criteria. However, using our alternative definition (at least moderate disease 
and subjectively absent or poor dopaminergic therapy response), 72 cases (3.6%) 
were categorized as non-PD, which increased the proportion of non-PD cases from 
8.3% to 11.2%.  
Considering the positive supportive MDS criteria, these were most prevalent in 
clinically established PD, and were considerably lower in clinically probable PD, but 
intermediate those not meeting PD criteria (Table 2). Red flags were present in 288 
of the 2000 cases (14.4%), of which the majority (234 cases, 81.3% of 288) were 
categorized as clinically probable PD (rather than non-PD) because of supportive 
features, reflecting the balancing approach in the MDS criteria [4]. (Table 2). There 
were 2 positive supportive criteria in 56.9% of the 1261 clinically established PD 
cases, and more than 2 such criteria in 43.1% of these cases. These supportive 
criteria were less common in clinically probable PD (2 criteria in 16.0%, more than 2 
criteria 16.7%), but were intermediate in those categorized as non-PD (2 criteria in 
39.4%, more than 2 criteria in 26.7%). 
After a mean follow-up of 2.5 (SD 0.6) years, the categorization of cases by MDS 
criteria as PD versus not PD was largely stable, compared to the baseline 
categorization (Table 3). Out of 165 non-PD at baseline, 156 (94.5%) remained as 
non-PD, and 9 (5.5%) were categorized as probable PD because of emergent 
supportive features, which balanced red flags. Clinically probable PD became 
clinically established PD due to the increased supporting features (to 2 or more) 
without any red flags (147 of 574 cases, 25.6%). Of the 1261 clinically established 
PD cases at baseline, 152 (12.1%) became clinically probable PD at follow-up, due 
to red flags emerging. Clinically probable PD cases at baseline remained probable, 
or became established, in 86.9% of cases. Clinically established PD cases at 
baseline remained established PD, or became clinically probable PD, in 89.5%. The 
number of cases categorized as not PD increased from 165 (8.3%) at baseline to 
364 (18.2%) at follow-up. The overall percent agreement comparing categorization at 
baseline to follow-up was 74.2% (actual), or 83.8% (weighted). The weighted Kappa 
was 0.55, while the weighted Gwet AC1/AC2 was 0.70. 
During follow-up, 32 cases had a change in clinical diagnosis, of which 21 cases 
were: MSA (n=5), PSP (n=5), essential or dystonic tremor (n=3), stroke (n=2), and 
single cases of dementia with Lewy bodies, corticobasal degeneration, functional 
parkinsonism, multiple sclerosis, post-polio syndrome, and spinal cord compression. 
The 11 remaining cases had inconclusive diagnoses: 4 with normal presynaptic 
dopaminergic functional imaging performed after study entry, and 7 not otherwise 
specified. Of the 32 cases with a revised diagnosis, 8 (25%) had been classified as 
non-PD by MDS criteria at baseline, which increased to 14 (43.8%) at follow-up; 10 
(31.2%) were classified as clinically probable PD at baseline, which declined to 7 
(21.9%) at follow-up; and 14 (43.8%) were classified as clinically established PD at 
baseline, which declined to 11 (34.4%) at follow-up. 
The clinicians’ assessment reported atypical clinical features that might raise 
diagnostic doubt in 181 cases (9.1%), and this was more common in cases 
categorized as non-PD by the MDS criteria (15.8%), compared to 12.0% in clinically 
probable cases, and 6.8% in clinically established cases. Clinicians rated the 
diagnostic certainty of PD at less than 90% in 521 cases (26.1%); 29.7% of the MDS 
non-PD cases had this <90% diagnostic certainty score, compared to 33.3% of those 
classified as clinically probable PD, and 22.3% of clinically established PD. 
 
Discussion 
Our study is the first to apply the new MDS diagnostic criteria for PD to a large scale 
cohort. We found that over 90% of patients, at an early disease stage and with 
cardinal motor features and a clinical diagnosis of PD, fulfilled the MDS criteria for 
PD at baseline (study entry), and a higher proportion was categorized as clinically 
established PD (more than 60%) than clinically probable PD (less than 30%). In our 
cohort, the MDS diagnostic criteria are therefore at least 90% sensitive compared to 
the most commonly used preceding criteria [5]. We found that categorization as not 
PD (under 10%) resulted almost exclusively from the presence of absolute exclusion 
criteria, rather than having more than 2 diagnostic red flags (only 1 case). Also, 
baseline categorization as ‘not PD’ affected one quarter of 32 cases with a later 
revised diagnosis, and this ‘not PD’ status increased to over 40% at 2.5 years.  
There were significant phenotypic differences between clinically established and 
clinically probable PD cases. Clinically established PD cases had more supporting 
diagnostic features than clinically probable PD cases, indicating that, when red flags 
are present, there are also fewer supporting criteria (by definition all clinically 
established PD cases have 2 or more supporting criteria; only around one third of 
clinically probable PD have 2 or more supporting criteria). Since rest tremor is one of 
the 4 supporting criteria, clinically established PD cases were therefore more likely to 
be tremor dominant, and less likely to have postural instability gait difficulty (PIGD)  
[8]. Clinically established PD cases were also more likely to have commenced anti-
parkinsonian medication, and were prescribed higher doses of dopaminergic therapy 
(around 25% greater than clinically probable cases).  
Given the critical significance of dopaminergic responsiveness to diagnostic 
accuracy [2, 3], both the supporting feature of a clear and dramatic response to 
dopaminergic therapy, and the absolute exclusion of an absent observable L-dopa 
response, are of particular importance. A good L-dopa response was present in 
those classified as clinically established PD (around 80%), but a significant 
proportion of cases (almost two-thirds) classified as non-PD also showed a good L-
dopa response. This may reflect the known early-stage dopa-responsiveness in 
disorders such as PSP [13, 14] and MSA [15], which wanes over time. Absence of 
the L-dopa response by MDS criteria involved very few cases (0.2%), largely 
because the required daily L-dopa dose of at least 600mg for this criterion was rare 
at this early disease stage. Our exploratory more inclusive definition of poor 
dopaminergic responsiveness identified more cases and increased the proportion of 
non-PD cases by around 3%. We will test whether this is a useful early indicator of a 
diagnosis other than PD during further follow-up. 
We also found that disease severity was significantly greater for cases categorized 
as non-PD compared to PD cases, including worse motor severity, more cases with 
PIGD, and more cases with dementia. This replicates the baseline features in the 
8.1% of 800 cases who entered the DATATOP study as PD but later underwent 
diagnostic revision to ‘not PD’, during 6 years mean follow-up [16]. In addition, the 
dopaminergic therapy dose was greater in ‘not PD’ cases using the MDS criteria. 
The cases identified by MDS criteria as atypical for PD therefore have more severe 
parkinsonism that is less responsive to dopaminergic therapy, suggesting that a 
majority of such cases have an atypical parkinsonian syndrome or comorbidity (e.g. 
cerebrovascular disease) [17, 18].  
The proportion of cases with a revised diagnosis during follow-up (1.6%) was 
considerably lower than the number of cases categorized either at baseline (8.3%) or 
after follow-up (18.2%) as non-PD by MDS criteria. However, our clinicians much 
more frequently recognized atypical features (9.1% of cases at baseline), suggesting 
that diagnostic revision is delayed until atypical features are more definite. However, 
clinical trials of emerging treatments, targeted to either abnormal alpha-synuclein or 
tau protein accumulation, would benefit from earlier distinction of these disorders. 
Our findings suggest that distinguishing features are present even at this relatively 
early stage, which is consistent with one previous long-duration clinical and autopsy 
study, in which early diagnostic clues were followed by definitive features, which 
improved the clinical accuracy (which was higher for PSP than for MSA) [19].  
The new MDS diagnostic criteria set targets for accurate case identification: 90% of 
clinically established cases should have Lewy body associated PD, and 80% of 
clinically probable cases [4]. As an indicator of this, we found the diagnostic PD 
categories to be stable: cases in both established and probable groups retained a 
PD categorization of around 85% after 2.5 years. However, within the PD groups, 
there was movement in both directions (around 1 in 10 clinically established cases 
became clinically probable, and around a quarter of clinically probable cases 
became clinically established). This helps to quantify the likelihood of emerging red 
flags, and the development of increased numbers of supporting features, both of 
which are central to the MDS criteria definitions. We also found support for a further 
aim of the MDS diagnostic criteria: that only 3% of cases categorized as non-PD 
would actually have PD [4]. We found that 7 cases (3.1%) changed category from 
not PD to clinically probable PD, because of the emergence of additional supporting 
features; the long-term validity of these observations will be tested in follow-up. 
Rest tremor is one of the cardinal motor signs of parkinsonism [20], and one of 4 
supporting features for PD, when present in a limb, in the MDS criteria [4]. However, 
rest tremor can be present in dystonia[21], essential tremor [22], PSP [23], MSA [24], 
functional disorders [25] and after stroke[26]. Rest tremor was not specific for PD 
(possible or probable) in one autopsy study [2]. In our cohort, limb rest tremor was 
common (around 70% of cases) in ‘not PD’ cases, against around 60% of clinically 
probable cases (although in clinically established PD it was almost 90%). 
Accordingly the MDS criteria help to emphasise the importance of other clinical 
features (red flags and exclusions) that are are inconsistent with a diagnosis of PD. 
There are certain limitations to our study design. As the MDS criteria were published 
after our study completed patient recruitment, there were some variations in 
definitions. By recording vertical gaze palsy, rather than downgaze palsy only, the 
number of cases categorized as non-PD may be increased. Our objective measure 
of L-dopa responsiveness was based on the patient’s usual morning L-dopa dose, 
which differs from the response after a change in medication defined by the MDS 
criteria. In addition, we did not have data regarding recurrent falls, inspiratory stridor, 
or disproportionate anterocollis, or results of imaging cardiac sympathetic 
denervation (although this is rarely applied), so we may have slightly overestimated 
clinically probable PD cases.  
In conclusion, the MDS criteria for PD are sensitive for detecting PD, amongst cases 
fulfilling the core definition of parkinsonism and with a clinical PD diagnosis, and 
helpful in categorizing levels of diagnostic certainty. Cases not fulfilling MDS 
diagnostic criteria for PD have more severe parkinsonism, in particular relating to 
postural instability, gait problems, and cognitive impairment.  
 
 
Acknowledgements 
The research was funded by Parkinson’s UK and supported by the National Institute 
for Health Research (NIHR) DeNDRoN network, the NIHR Newcastle Biomedical 
Research Unit based at Newcastle upon Tyne Hospitals NHS Foundation Trust and 
Newcastle University, and the NIHR funded Biomedical Research Centre in 
Cambridge.  The views expressed are those of the authors and not necessarily those 
of the NHS, the NIHR or the Department of Health. 
Author contributions: 
NM: Data collection, analysis, manuscript writing and editing 
ML: Data analysis, manuscript writing and editing 
NB, RAB, DJB, HRM: Data collection, study design, manuscript editing 
JH, NW, NW: Study design 
YBS: Study design, data analysis plan, manuscript editing 
KAG, DGG: Study design, data collection, analysis, manuscript writing and editing 
 
Financial disclosures: 
N Malek, KA Grosset, MA Lawton, N Williams, Y Ben-Shlomo: No conflicts of interest 
N Bajaj has received payment for advisory board attendance from UCB, Teva 
Lundbeck, Britannia, GSK, Boehringer, and honoraria from UCB Pharma, GE 
Healthcare, Lily Pharma, Medtronic. He has received research grant support from 
GE Healthcare, Wellcome Trust, Medical Research Council, Parkinson’s UK and 
National Institute for Health Research. 
RA Barker has received grants from Parkinson’s UK, NIHR, Cure Parkinson’s Trust, 
Evelyn Trust, Rosetrees Trust, MRC and EU along with payment for advisory board 
attendance from Oxford Biomedica and LCT, and honoraria from Lilley, Wiley and 
Springer.  
DJ Burn has received grants from NIHR, Wellcome Trust, GlaxoSmithKline Ltd, 
Parkinson’s UK, and Michael J Fox Foundation.  He has acted as consultant for 
GSK.  
J Hardy has received honoraria from Eisai, and grant support from MRC/Wellcome, 
Parkinson’s UK, and the Michael J Fox Foundation.  
H R Morris has received grants from Medical Research Council UK, Wellcome Trust, 
Parkinson’s UK, Ipsen Fund, Motor Neurone Disease Association, Welsh Assembly 
Government, PSP Association, CBD Solutions and Drake Foundation, and payment 
for advisory board attendance and lectures from Teva, AbbVie, Boehringer 
Ingelheim, and GSK. 
DG Grosset has received payment for advisory board attendance from AbbVie, and 
honoraria from UCB Pharma, GE Healthcare, Civitas, and Acorda. 
 
 
  
References 
 
 
[1] E.R. Dorsey, R. Constantinescu, J.P. Thompson, K.M. Biglan, R.G. Holloway, K. Kieburtz, F.J. 
Marshall, B.M. Ravina, G. Schifitto, A. Siderowf, C.M. Tanner, Projected number of people with 
Parkinson disease in the most populous nations, 2005 through 2030, Neurology 68(5) (2007) 384-6. 
[2] C.H. Adler, T.G. Beach, J.G. Hentz, H.A. Shill, J.N. Caviness, E. Driver-Dunckley, M.N. 
Sabbagh, L.I. Sue, S.A. Jacobson, C.M. Belden, B.N. Dugger, Low clinical diagnostic accuracy of 
early vs advanced Parkinson disease: clinicopathologic study, Neurology 83(5) (2014) 406-12. 
[3] G. Rizzo, M. Copetti, S. Arcuti, D. Martino, A. Fontana, G. Logroscino, Accuracy of clinical 
diagnosis of Parkinson disease: A systematic review and meta-analysis, Neurology 86(6) (2016) 566-
76. 
[4] R.B. Postuma, D. Berg, M. Stern, W. Poewe, C.W. Olanow, W. Oertel, J. Obeso, K. Marek, I. 
Litvan, A.E. Lang, G. Halliday, C.G. Goetz, T. Gasser, B. Dubois, P. Chan, B.R. Bloem, C.H. Adler, 
G. Deuschl, MDS clinical diagnostic criteria for Parkinson's disease, Mov. Disord. 30(12) (2015) 
1591-601. 
[5] A.J. Hughes, S.E. Daniel, A.J. Lees, Improved accuracy of clinical diagnosis of Lewy body 
Parkinson's disease, Neurology 57(8) (2001) 1497-9. 
[6] N. Malek, D.M. Swallow, K.A. Grosset, M.A. Lawton, S.L. Marrinan, A.C. Lehn, C. Bresner, N. 
Bajaj, R.A. Barker, Y. Ben-Shlomo, D.J. Burn, T. Foltynie, J. Hardy, H.R. Morris, N.M. Williams, N. 
Wood, D.G. Grosset, Tracking Parkinson's: Study Design and Baseline Patient Data, Journal of 
Parkinson's disease 5(4) (2015) 947-59. 
[7] C.L. Tomlinson, R. Stowe, S. Patel, C. Rick, R. Gray, C.E. Clarke, Systematic review of levodopa 
dose equivalency reporting in Parkinson's disease, Mov. Disord. 25(15) (2010) 2649-53. 
[8] G.T. Stebbins, C.G. Goetz, D.J. Burn, J. Jankovic, T.K. Khoo, B.C. Tilley, How to identify tremor 
dominant and postural instability/gait difficulty groups with the movement disorder society unified 
Parkinson's disease rating scale: comparison with the unified Parkinson's disease rating scale, Mov. 
Disord. 28(5) (2013) 668-70. 
[9] M. Emre, D. Aarsland, R. Brown, D.J. Burn, C. Duyckaerts, Y. Mizuno, G.A. Broe, J. Cummings, 
D.W. Dickson, S. Gauthier, J. Goldman, C. Goetz, A. Korczyn, A. Lees, R. Levy, I. Litvan, I. 
McKeith, W. Olanow, W. Poewe, N. Quinn, C. Sampaio, E. Tolosa, B. Dubois, Clinical diagnostic 
criteria for dementia associated with Parkinson's disease, Mov. Disord. 22(12) (2007) 1689-707; quiz 
1837. 
[10] M. Lawton, M.T. Hu, F. Baig, C. Ruffmann, E. Barron, D.M. Swallow, N. Malek, K.A. Grosset, 
N. Bajaj, R.A. Barker, N. Williams, D.J. Burn, T. Foltynie, H.R. Morris, N.W. Wood, M.T. May, 
D.G. Grosset, Y. Ben-Shlomo, Equating scores of the University of Pennsylvania Smell Identification 
Test and Sniffin' Sticks test in patients with Parkinson's disease, Parkinsonism & related disorders 33 
(2016) 96-101. 
[11] A.R. Feinstein, D.V. Cicchetti, High agreement but low kappa: I. The problems of two 
paradoxes, J. Clin. Epidemiol. 43(6) (1990) 543-9. 
[12] K.L. Gwet, Computing inter-rater reliability and its variance in the presence of high agreement, 
Br. J. Math. Stat. Psychol. 61(Pt 1) (2008) 29-48. 
[13] D.R. Williams, I. Litvan, Parkinsonian syndromes, Continuum (Minneapolis, Minn.) 19(5 
Movement Disorders) (2013) 1189-212. 
[14] D.R. Williams, R. de Silva, D.C. Paviour, A. Pittman, H.C. Watt, L. Kilford, J.L. Holton, T. 
Revesz, A.J. Lees, Characteristics of two distinct clinical phenotypes in pathologically proven 
progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism, Brain 128(Pt 6) 
(2005) 1247-58. 
[15] C. Starhof, L. Korbo, C.F. Lassen, K. Winge, S. Friis, Clinical Features in a Danish Population-
Based Cohort of Probable Multiple System Atrophy Patients, Neuroepidemiology 46(4) (2016) 261-7. 
[16] J. Jankovic, A.H. Rajput, M.P. McDermott, D.P. Perl, The evolution of diagnosis in early 
Parkinson disease. Parkinson Study Group, Arch. Neurol. 57(3) (2000) 369-72. 
[17] N. Malek, M.A. Lawton, D.M. Swallow, K.A. Grosset, S.L. Marrinan, N. Bajaj, R.A. Barker, 
D.J. Burn, J. Hardy, H.R. Morris, N.M. Williams, N. Wood, Y. Ben-Shlomo, D.G. Grosset, Vascular 
disease and vascular risk factors in relation to motor features and cognition in early Parkinson's 
disease, Mov. Disord. 31(10) (2016) 1518-1526. 
[18] D.M. Swallow, M.A. Lawton, K.A. Grosset, N. Malek, J. Klein, F. Baig, C. Ruffmann, N.P. 
Bajaj, R.A. Barker, Y. Ben-Shlomo, D.J. Burn, T. Foltynie, H.R. Morris, N. Williams, N.W. Wood, 
M.T. Hu, D.G. Grosset, Statins are underused in recent-onset Parkinson's disease with increased 
vascular risk: findings from the UK Tracking Parkinson's and Oxford Parkinson's Disease Centre 
(OPDC) discovery cohorts, J. Neurol. Neurosurg. Psychiatry 87(11) (2016) 1183-1190. 
[19] A.H. Rajput, B. Rozdilsky, A. Rajput, Accuracy of clinical diagnosis in parkinsonism--a 
prospective study, Can. J. Neurol. Sci. 18(3) (1991) 275-8. 
[20] A.J. Hughes, S.E. Daniel, S. Blankson, A.J. Lees, A clinicopathologic study of 100 cases of 
Parkinson's disease, Arch. Neurol. 50(2) (1993) 140-8. 
[21] A.F. Gigante, A. Berardelli, G. Defazio, Rest tremor in idiopathic adult-onset dystonia, Eur. J. 
Neurol. 23(5) (2016) 935-939. 
[22] O. Cohen, S. Pullman, E. Jurewicz, D. Watner, E.D. Louis, Rest tremor in patients with essential 
tremor: prevalence, clinical correlates, and electrophysiologic characteristics, Arch. Neurol. 60(3) 
(2003) 405-10. 
[23] G. Respondek, M. Stamelou, C. Kurz, L.W. Ferguson, A. Rajput, W.Z. Chiu, J.C. van Swieten, 
C. Troakes, S. Al Sarraj, E. Gelpi, C. Gaig, E. Tolosa, W.H. Oertel, A. Giese, S. Roeber, T. 
Arzberger, S. Wagenpfeil, G.U. Hoglinger, The phenotypic spectrum of progressive supranuclear 
palsy: a retrospective multicenter study of 100 definite cases, Mov. Disord. 29(14) (2014) 1758-66. 
[24] C. Kaindlstorfer, R. Granata, G.K. Wenning, Tremor in Multiple System Atrophy - a review, 
Tremor and other hyperkinetic movements (New York, N.Y.) 3 (2013). 
[25] J.I. Sage, M.H. Mark, Psychogenic parkinsonism: clinical spectrum and diagnosis, Ann. Clin. 
Psychiatry 27(1) (2015) 33-8. 
[26] F. Alarcón, J.C.M. Zijlmans, G. Dueñas, N. Cevallos, Post-stroke movement disorders: report of 
56 patients, J. Neurol. Neurosurg. Psychiatry 75(11) (2004) 1568-1574. 
 
 
Table 1. Demographic and disease features in 2000 cases with a clinical diagnosis of recent onset Parkinson’s disease, 
categorized according to fulfilment of MDS diagnostic criteria for PD. 
 
  Fulfilment of MDS criteria for PD Adjusted p-values 
Characteristic 
All cases 
N=2000 
(100%) 
Not PD 
N=165 
(8.3%) 
Clinically probable 
N=574 
(28.7%) 
Clinically 
established 
N=1261 
(63.1%) 
Not PD vs 
Clinically 
probable 
Not PD vs 
Clinically 
established 
Clinically 
probable 
vs 
Clinically 
established 
Age at onset 
64.4 (9.8) 64.7 (9.7) 65.2 (9.9) 64.0 (9.7) 0.61a 0.39 a 0.021 a 
Age at diagnosis 
66.2 (9.3) 66.5 (9.0) 67.1 (9.4) 65.8 (9.3) 0.49 a 0.41 a 0.010 a 
Age at baseline 
67.6 (9.3) 67.8 (9.0) 68.3 (9.4) 67.2 (9.3) 0.49 a 0.41 a 0.010 a 
Disease duration 
1.3 (0.9) 1.4 (0.9) 1.2 (0.9) 1.4 (0.9) 0.084b 0.77 b <0.001 b 
Gender (Male) 
1299 (64.9%) 104 (63.0%) 369 (64.3%) 826 (65.5%) 0.80c 0.51 c 0.52 c 
Symptoms at onset 
       
Tremor 
1452 (74.4%) 102 (62.6%) 310 (57.4%) 1040 (83.3%) 0.19d <0.001 d <0.001 d 
Rigidity 
1337 (71.9%) 114 (76.0%) 365 (70.1%) 858 (72.2%) 0.15 d 0.32 d 0.37 d 
Bradykinesia 
1493 (78.5%) 128 (81.5%) 411 (77.1%) 954 (78.7%) 0.21 d 0.43 d 0.35 d 
Postural instability 
364 (19.8%) 48 (31.0%) 114 (22.0%) 202 (17.4%) 0.012 d <0.001 d 0.083 d 
Motor Subtype 
       
Tremor Dominant 
832 (45.9%) 46 (31.3%) 210 (41.3%) 576 (49.8%)    
PIGD 
745 (41.1%) 86 (58.5%) 244 (47.9%) 415 (35.9%) 0.022 d <0.001 d <0.001 d 
Indeterminate 
236 (13.0%) 15 (10.2%) 55 (10.8%) 166 (14.3%) 0.54 d 0.69 d 0.65 d 
MoCA 
       
Normal 
1342 (73.2%) 100 (65.8%) 386 (74.1%) 856 (73.7%) 0.013 d 0.020 d 0.59 d 
MCI 
227 (12.4%) 19 (12.5%) 54 (10.4%) 154 (13.3%)    
Dementia 
265 (14.4%) 33 (21.7%) 81 (15.5%) 151 (13.0%)    
MDS UPDRS 3 
22.9 (12.3) 25.1 (13.2) 22.3 (12.7) 22.9 (12.0) 0.016 d 0.066 d 0.22 d 
Hoehn and Yahr  
       
0 - 1.5 
948 (47.9%) 69 (41.8%) 283 (50.8%) 596 (47.4%) 0.063 d 0.25 d 0.18 d 
2 - 2.5 
894 (45.2%) 69 (41.8%) 239 (42.9%) 586 (46.6%) <0.001 d <0.001 d 0.72 d 
3 + 
137 (6.9%) 27 (16.4%) 35 (6.3%) 75 (6.0%)    
Untreated 
196 (9.8%) 17 (10.3%) 92 (16.1%) 87 (6.9%) 0.11 d 0.12 d <0.001 d 
LEDD (mg per day) 
294 (211) 341 (261) 250 (214) 308 (199) <0.001 d 0.025 d <0.001 d 
Data are shown as mean and standard deviation or n%. MDS = Movement Disorder Society, PD = Parkinson’s disease, UPDRS 3 = Unified Parkinson’s 
disease rating scale Part 3, LEDD = levodopa equivalent daily dose, PIGD = postural instability and gait difficulty, MoCA = Montreal Cognitive Assessment 
aAdjusted for sex and disease duration 
bAdjusted for age and sex 
cAdjusted for age and disease duration 
dAdjusted for sex, age and disease duration 
Table 2. Fulfilment of MDS criteria in 2000 cases with a clinical diagnosis of recent 
onset Parkinson’s disease. 
 
 Fulfilment of MDS criteria for Parkinson’s disease 
 
Characteristic 
All cases 
N=2000 
(100%) 
Not PD 
N=165 (8.3%) 
Clinically 
probable 
N=574 (28.7%) 
Clinically 
established 
N= 1261 
(63.1%) 
Number of red flags     
0 
1712 
(85.6%) 
111 
(67.3%) 
340 
(59.2%) 
1261  
(100%) 
1 
251 
(12.6%) 
41 
(24.8%) 
210 
(36.6%) 
NA 
2 
36 
(1.8%) 
12 
(7.3%) 
24 
(4.2%) 
NA 
>2 
1 
(0.1%) 
1 
(0.6%) 
0 
(0.0%) 
NA 
Number of supporting criteria   
0 
55 
(2.8%) 
13 
(7.9%) 
42 
(7.3%) 
NA 
1 
387 
(19.4%) 
43 
(26.1%) 
344 
(59.9%) 
NA 
2 
874 
(43.7%) 
65 
(39.4%) 
92 
(16.0%) 
717 
(56.9%) 
>2 
684 
(34.2%) 
44 (26.7%) 96 (16.7%) 
544 
(43.1%) 
Number of absolute exclusion criteria   
0 
1851 
(92.6%) 
16 
(9.7%) 
574 
(100.0%) 
1261 
(100%) 
1 
143 
(7.2%) 
143 
(86.7%) 
NA 
Not 
applicab
le 
>1 
6 
(0.3%) 
6 
(3.6%) 
NA 
Not 
Applicab
le 
 
 
  
 
 
 
Fulfilment of MDS criteria for Parkinson’s disease 
 
Characteristic 
All cases 
N=2000 
(100%) 
Not PD 
N=165 (8.3%) 
Clinically 
probable 
N=574 (28.7%) 
Clinically 
established 
N= 1261 
(63.1%) 
Absence of motor progression 0 (0.0%) 0 (0.0%) 0 (0.0%) NA 
Bulbar dysfunction 115 (5.8%) 29 (17.6%) 86 (15.0%) NA 
Respiratory dysfunction 0 (0.0%) 0 (0.0%) 0 (0.0%) NA 
Severe autonomic 148 (7.4%) 25 (15.2%) 123 (21.4%) NA 
Recurrent falls 0 (0.0%) 0 (0.0%) 0 (0.0%) NA 
Disproportionate anterocollis 0 (0.0%) 0 (0.0%) 0 (0.0%) NA 
Common non-motor absent 0 (0.0%) 0 (0.0%) 0 (0.0%) NA 
Pyramidal signs 36 (1.8%) 9 (5.5%) 27 (4.7%) NA 
Symmetric parkinsonism 24 (1.2%) 5 (3.0%) 19 (3.3%) NA 
Supporting criteria     
Clear L-dopa response 1363 (68.2%) 105 (63.6%) 255 (44.4%) 
1003 
(79.5%) 
L-dopa induced dyskinesia 94 (4.7%) 7 (4.2%) 22 (3.8%) 
65  
(5.2%) 
Rest tremor of a limb 1585 (79.3%) 111 (67.3%) 348 (60.6%) 
1126  
(89.3%) 
Olfactory loss 1181 (59.0%) 87 (52.7%) 198 (34.5%) 
896 
(71.1%) 
Absolute exclusion criteria     
Unequivocal cerebellar 25 (1.3%) 25 (15.2%) NA NA 
Vertical gaze palsy 117 (5.8%) 117 (70.9%) NA NA 
Fronto-temporal 
dementia/PPA 
0 (0.0%) 0 (0.0%) NA NA 
Parkinsonism in lower limbs 
only 
1 (0.1%) 1 (0.6%) NA NA 
Dopamine blocker / depleter 2 (0.1%) 2 (1.2%) NA NA 
Absence of L-dopa response 3 (0.2%) 3 (1.8%) NA NA 
Cortical sensory loss / apraxia 8 (0.4%) 8 (4.8%) NA NA 
Normal functional dopamine 
imaging 
0 (0.0%) 0 (0.0%) NA NA 
Alternative parkinsonism  0 (0.0%) 0 (0.0%) NA NA 
MDS = Movement Disorder Society, NA = Not applicable, PD = Parkinson’s disease, PPA = Primary 
progressive aphasia  
Table 3. Stability of MDS categorization of Parkinson’s disease, comparing baseline 
and 2.5 years’ follow-up. 
 
 
Follow-up analysis 
Baseline 
analysis Not PD Probable PD Established PD % probable or 
established PD 
Not PD  
N=165 
156 9 0 5.5% 
Probable PD 
N=574 
76 351 147 86.8% 
Established PD 
N=1261 
132 152 977 89.5% 
MDS = Movement Disorder Society, PD = Parkinson’s disease 
 
Supplementary Table 1. Diagnostic categorization and features in 31 cases who had a 
revised clinical diagnosis. 
 
Revised 
diagnosis 
Case 
number 
MDS baseline 
categorization 
Number 
(type) of 
exclusions 
Number of 
red flags 
Number of 
supporting 
criteria 
Multiple 
system atrophy 
1 Established 0 0 2 (response, 
tremor) 
2 Probable 0 2 (bulbar, 
autonomic) 
2 (response, 
tremor) 
3 Probable 0 0 0 
4 Probable 0  0 1 (tremor) 
5 Probable 0 1 
(autonomic) 
2 (response, 
tremor) 
 6 Probable 0 0 1 (olfaction) 
Progressive 
supranuclear 
palsy 
1 Established 0 0 3 (response, 
tremor, 
olfaction) 
2 Established 0 0 2 (response, 
olfaction) 
3 Established 0 0 2 (response, 
tremor) 
4 Not PD 1 (gaze palsy) 0 1 (response) 
5 Not PD 1 (gaze palsy) 0 1 (response) 
Essential or 
dystonic tremor 
1 Established 0 0 2 (response, 
tremor) 
2 Probable 0 0 1 (tremor) 
3 Not PD 1 (gaze palsy) 0 1 (tremor) 
Normal 
functional 
dopamine 
imaging 
1 Established 0 0 2 (response, 
tremor) 
2 Probable 0 0 1 (tremor) 
3 Probable 0 0 1 (olfaction) 
4 Probable 0 1 
(autonomic) 
2 (response, 
olfaction) 
Vascular 
parkinsonism 
1 Established 0 0 2 (response, 
tremor) 
2 Established 0 0 2 (response, 
tremor) 
Corticobasal 
degeneration 
1 Not PD 2 (cerebellar, 
cortical 
sensory loss) 
0 1 (response) 
Multiple 
sclerosis 
1 Established 0 0 2 (response, 
olfaction) 
Post-polio 
syndrome 
1 Established 0 0 2 (response, 
olfaction) 
Spinal cord 
compression 
1 Established  0 0 3 (response, 
tremor, 
olfaction) 
Functional 1 Established 0 0 2 (response, 
tremor) 
Unknown but 
not PD 
1 Established 0 0 2 (tremor, 
dyskinesia) 
2 Established 0 0 3 (response, 
tremor, 
olfaction) 
3 Probable 0 1 
(autonomic) 
3 (response, 
tremor, 
olfaction) 
4 Probable 0 0 1 (response) 
5 Probable 0 1 
(autonomic) 
1 (response) 
6 Not PD 1 (gaze palsy) 0 1 (tremor) 
MDS = Movement Disorder Society, PD = Parkinson’s disease, response = L-dopa response, 
tremor = rest tremor 
 
